Table 4.
Evidence overview of combined solifenacin 5–6 mg plus tamsulosin 0.2–0.4 mg versus tamsulosin 0.2–0.4 mg monotherapy
| Outcome | No. of trials (evaluated) | Intervention, % (n/N) or mean | Control, % (n/N) or mean | Results and magnitude of effect (95% CI) | Strength of evidence |
|---|---|---|---|---|---|
| Responders | Not reported | Insufficient | |||
| I-PSS score, mean change from baseline | 6 (1948) | −5.8 points | −5.4 points | Similar between groups: WMD −0.29 (−0.88–0.30) |
Moderatea |
| I-PSS QoL, mean change from baseline | 4 (1225) | −1.2 points | −0.9 points | Similar between groups: WMD −0.18 (−0.39 to −0.03) |
Moderatea |
| Overall withdrawals | 7 (3147) | 10 (203/2028) | 11 (121/1119) | Similar between groups: RR 1.02 (0.74–1.41) |
Lowa,b |
| Withdrawals due to adverse effects | 5 (2900) | 4 (71/1904) | 3 (30/996) | Similar between groups: RR 1.27 (0.81–2.0) |
Lowa,b |
| Participants with ≥1 adverse effect | 5 (2918) | 33 (623/1913) | 29 (280/1005) | Greater with combined therapy: RR 1.21 (1.09–1.35) |
Moderatea |
CI = confidence intervals; I-PSS = International Prostate Symptom Score; QoL = quality of life; RR = risk ratio; WMD = weighted mean difference.
Downgraded based on the following:
a
Risk of bias (moderate).
b
Imprecision.